Gossamer Bio, Inc. is highlighted as one of the 15 Best Biotech Penny Stocks to Invest in Right Now, focusing on seralutinib for PAH and PH-ILD. The company’s stock rose 18% in September 2025 due to FDA designations and positive seralutinib pipeline updates, positioning it as a strong player in the market.

Despite a net loss of $38.3 million and negative shareholder equity, Gossamer Bio, Inc. maintains near 100% gross margins, indicating potential profitability upon commercialization. Analysts are optimistic about the ongoing Phase 3 PROSERA study, which could lead to regulatory approval and market access for seralutinib in the PAH market.

While Gossamer Bio, Inc. presents investment potential, other AI stocks may offer greater upside and lower risk. For those seeking undervalued AI stocks benefiting from current trends, a free report on the best short-term AI stock is available.

Read more at Yahoo Finance: Gossamer Bio, Inc. (GOSS) Stock Jumps 18% on FDA Updates and Seralutinib Progress